AbbVie Inc (ABBV) : Sawgrass Asset Management scooped up 97,885 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 402,725 shares of AbbVie Inc which is valued at $26,809,403.AbbVie Inc makes up approximately 1.22% of Sawgrass Asset Management’s portfolio.
Other Hedge Funds, Including , Dumont Blake Investment Advisors reduced its stake in ABBV by selling 600 shares or 2.68% in the most recent quarter. The Hedge Fund company now holds 21,755 shares of ABBV which is valued at $1,448,230. AbbVie Inc makes up approx 0.71% of Dumont Blake Investment Advisors’s portfolio.Btc Capital Management boosted its stake in ABBV in the latest quarter, The investment management firm added 1,022 additional shares and now holds a total of 34,359 shares of AbbVie Inc which is valued at $2,287,279. AbbVie Inc makes up approx 0.48% of Btc Capital Management’s portfolio.Shell Asset Management Co boosted its stake in ABBV in the latest quarter, The investment management firm added 34,604 additional shares and now holds a total of 166,992 shares of AbbVie Inc which is valued at $10,837,781. AbbVie Inc makes up approx 0.25% of Shell Asset Management Co’s portfolio.Independence Trust Co reduced its stake in ABBV by selling 520 shares or 2.09% in the most recent quarter. The Hedge Fund company now holds 24,403 shares of ABBV which is valued at $1,557,155. AbbVie Inc makes up approx 2.33% of Independence Trust Co’s portfolio.
AbbVie Inc closed down -0.2 points or -0.30% at $66.34 with 53,09,293 shares getting traded on Monday. Post opening the session at $66.38, the shares hit an intraday low of $65.75 and an intraday high of $66.67 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.